Before Myovant, Seely was chief medical officer at Medivation Inc., overseeing the San Francisco company's late-stage clinical failure with an Alzheimer's Disease drug as well as its successful development of the prostate cancer drug Xtandi before the company wasAt Lyell, she moves into the corner office as the company moves it two cancer cell therapies through the clinic, aiming to reprogram infection-fighting T cells.
"Since becoming a member of Lyell's board, I've been impressed with Lyell's groundbreaking science, state-of-the-art manufacturing capabilities and the passion and commitment of the Lyell team to make a transformative difference in the lives of patients with solid tumors," Seely said in a company statement., who now is chairman of the Lyell board, and Homans was one of the first six employees.
Homans, who spent four years as president and then CEO after more than 10 years at Genentech Inc. and Roche, said through the company that the"decision to transition from my role at Lyell was a difficult one, but I am excited about the next chapter for the company under Lynn's leadership."